

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

1. (currently amended) A method for inhibiting maturation of dendritic cells for the treatment of a pulmonary disease ~~which is directly or indirectly associated to selected from idiopathic pulmonary disease fibrosis, hypersensitive pneumonia or diffused panbronchiolitis~~, comprising administering to a patient a peptide or a polypeptide comprising the following amino acid sequence:
Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO: 4).

2. (currently amended) The method according to claim 1, wherein said peptide or polypeptide further comprises at least one of the following amino acid sequence sequences:
His-Ser-Asp (SEQ ID NO: 14); and Phe-Thr-Asp (SEQ ID NO:13).

3. (currently amended) The method according to claim 1, wherein said peptide or polypeptide has having the following amino acid sequence:
(A)_n-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-(B)_m
wherein
(A)_n and (B)_m independently are primary amino acid sequences comprising any sequence of natural occurring amino acids;
wherein n has a value from 0 to 25 and n is the number of amino acid residues in said primary amino acid sequence (A)_n; and
wherein m has a value from 0 to 25 and m is the number of amino acid residues in said primary amino acid sequence (B)_m.

4. (previously presented) The method according to claim 3, wherein if n > 2, said primary amino acid sequence (A)_n further comprises a primary amino acid sequence:
(X)_o-Phe-Thr-Asp-(Y)_p;
wherein (X)_o and (Y)_p independently are primary amino acid sequences

comprising any sequence of natural occurring amino acids;
wherein o has a value from 0 to 11 and o is the number of amino acid residues in
said primary amino acid sequence (X)_o; and
wherein p has a value from 0 to 11 and p is the number of amino acid residues in
said primary amino acid sequence (Y)_p.

5. (previously presented) The method according to claim 4, wherein if o > 2, said primary amino acid sequence (A)_n further comprises a primary amino acid sequence:

(X')_q-His-Ser-Asp-(X'')_r

Wherein (X')_q and (X'')_r independently are primary amino acid sequences comprising any sequence of natural occurring amino acids;
wherein q has a value from 0 to 4 and q is the number of amino acid residues in said primary amino acid sequence (X')_q; and
wherein r has a value from 0 to 4 and r is the number of amino acid residues in said primary amino acid sequence (X'')_r.

6. (currently amended) The method according to claim 3, wherein the sequence of said peptide or polypeptide is selected from the following group:

- (i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO: 4);
- (ii) Phe-Thr-Asp-X¹-X²-X³-X⁴-X⁵-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO: 5);
- (iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg- -Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu.Asn-Ser-Ile-Leu-Asn (SEQ ID NO: 6);
- (iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu- (SEQ ID NO:7)
- (v) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys- Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO: 9);

- (vi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO: 10);
- (vii) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X⁸-X⁹-X¹⁰-X¹¹ (-X¹²) (SEQ ID NO: 11);
- (viii) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (VIP, SEQ ID NO: 1);
- (ix) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (PACAP-38) (SEQ ID NO: 2);
- (x) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-X²² (SEQ ID NO: 12); and
- (xi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-27, SEQ ID NO: 3); and

wherein X¹ - X²² [[is]] are any naturally occurring amino acid residue.

7. (previously presented) The method according to claim 1, wherein any said peptide or polypeptide is an analogue or derivative with the same biological function.
8. (previously presented) The method according to claim 7, wherein any said peptide or polypeptide is in a stabilized form.
9. (previously presented) The method according to claim 1, wherein said disease is idiopathic pulmonary fibrosis.

10. (previously presented) The method according to claim 1, wherein said disease is hypersensitive pneumonia.
11. (previously presented) The method according to claim 1, wherein said disease is diffused panbronchiolitis.
12. (previously presented) The method according to claim 1, wherein the therapeutically effective peptides are administered as aerosols.
13. (previously presented) The method according to claim 2, wherein said disease is idiopathic pulmonary fibrosis.
14. (previously presented) The method according to claim 2, wherein said disease is hypersensitive pneumonia.
15. (previously presented) The method according to claim 2, wherein the therapeutically effective peptides are administered as aerosols.
16. (previously presented) The method according to claim 3, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.
17. (previously presented) The method according to claim 3, wherein said disease is diffused panbronchiolitis.
18. (previously presented) The method according to claim 3, wherein the therapeutically effective peptides are administered as aerosols.